E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hereditary Angioedema Types I and II |
Angioedema Ereditario Tipo I e II |
|
E.1.1.1 | Medical condition in easily understood language |
HAE (type I and II) are genetic disorders that are associated with a deficiency in C1-INH. |
AE (tipo I e II) sono disordini genetici associati ad una carenza di C1INH |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10019860 |
E.1.2 | Term | Hereditary angioedema |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the clinical safety of subcutaneously administered C1-INH in the long-term prophylactic treatment of HAE. |
valutare la sicurezza clinica di C1-INH somministrato per via sottocutanea nel trattamento profilattico a lungo termine di HAE. |
|
E.2.2 | Secondary objectives of the trial |
To further characterize the clinical safety of subcutaneously administered C1-INH in the long-term prophylactic treatment of HAE. • To characterize the clinical efficacy of subcutaneously administered C1-INH in the long-term prophylactic treatment of HAE." |
caratterizzare ulteriormente la sicurezza clinica di C1-INH somministrato per via sottocutanea nel trattamento profilattico a lungo termine di HAE. • caratterizzare l'efficacia clinica di C1-INH somministrato per via sottocutanea nel trattamento profilattico a lungo termine dell'HAE . |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
"• Males or females aged 6 years or older. • A confirmed diagnosis of HAE type I or II. • HAE attacks over a consecutive 2-month period that required acute treatment, medical attention, or caused significant functional impairment. • For subjects who have used oral therapy for prophylaxis against HAE attacks within 3 months of first study visit: use of a stable regimen within 3 months of the first study visit." |
maschi o femmine dai 6 anni o più grandi. • diagnosi confermata di HAE di tipo I o II • attacchi di angioedema ereditario nel corso di un periodo consecutivo di 2 mesi che ha richiesto trattamento intensivo, medico, o causato perdita significativa di valore funzionale. • soggetti che hanno utilizzato la terapia orale per la profilassi contro attacchi HAE entro 3 mesi dalla prima visita di studio: l'uso di un regime stabile entro 3 mesi dalla prima visita di studio. " |
|
E.4 | Principal exclusion criteria |
Incurable malignancies. - Any clinical condition that will interfere with the evaluation of C1-INH therapy. - Clinically significant history of poor response to C1-esterase therapy for the management of HAE. - Suspected or confirmed diagnosis of acquired HAE or HAE with normal C1-INH. • Inability to have HAE managed pharmacologically with on-demand treatment |
Tumori incurabili. - Qualsiasi condizione clinica che possa interferire con la valutazione della terapia C1-INH - storia clinicamentedi significativa di scarsa risposta alla terapia C1-esterasi per la gestione di HAE. • Sospetta o confermata la diagnosi di HAE acquisito o HAE con normale C1-INH. • Incapacità di avere HAE gestito farmacologicamente con on-demand trattamento |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The person-time incidence rates of specified safety events. |
I tassi di incidenza persona-tempo di specificati eventi di sicurezza. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
During the treatment phase, up to 52 weeks |
Durante la fase di trattamento, fino a 52 settimane
|
|
E.5.2 | Secondary end point(s) |
Percentage of subjects with SAEs or other specified safety events. - Percentage of C1-INH injections resulting in solicited AEs (injection site reactions). - Percentage of subjects with at least 1 solicited AE (injection site reaction). - Percentage of subjects who become seropositive for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus. - Percentage of subjects who experience < 1 HAE attack per 4-week period. - Percentage of subjects with a ≥ 50% reduction in the time-normalized number of HAE attacks |
- Percentuale di soggetti con effetti indesiderati gravi o altri eventi di sicurezza specificati. - Percentuale conseguente di iniezioni di C1-INH in reazioni avverse sollecitate (reazioni nel sito di iniezione). - Percentuale di soggetti con almeno 1 AE sollecitato (reazione al sito di iniezione). - Percentuale di soggetti che diventano sieropositivi al virus dell'immunodeficienza, dell'epatite B, o dell'epatite C. - Percentuale di soggetti che sperimentano <1 attacco di AE per un period di 4 settimane periodo. - Percentuale di soggetti con riduzione ≥ 50% nel tempo normalizzata del numero di attacchi di angioedema ereditario |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
During the treatment phase, up to 52 weeks. - During the treatment phase, up to 52 weeks. - During the treatment phase, up to 52 weeks. - From baseline through the treatment phase, up to 52 weeks. - During the treatment phase, up to 52 weeks. - From baseline through the treatment phase, up to 52 weeks. |
Durante la fase di trattamento, fino a 52 settimane. - Durante la fase di trattamento, fino a 52 settimane. - Durante la fase di trattamento, fino a 52 settimane. - Dalla linea di base attraverso la fase di trattamento, fino a 52 settimane. - Durante la fase di trattamento, fino a 52 settimane. - Dalla linea di base attraverso la fase di trattamento, fino a 52 settimane. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 15 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
Israel |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 0 |